44 results about "T cell differentiation" patented technology

The invention provides a method for preparing an anti-tumor T cell in vitro through DC (dendritic cell, namely antigen presenting cell), wherein the anti-tumor T cell is a tumor total RNA-loaded DC amplification and enrichment anti-tumor T cell. The invention also provides a preparation method of the anti-tumor T cell and an anti-tumor drug or inoculation vaccine taking the anti-tumor T cell as an active ingredient. According to the invention, a specific anti-tumor T cell is amplified in vitro by taking the tumor total RNA-loaded DC as a platform, a small amount of tumor total RNA is amplified to an enough amount in vitro so as to realize clinical application, and the in-vivo anti-tumor effect in an IC (intracranial) tumor-bearing model is evaluated, including how the mature state of DC and the cell factor combination adjust the differentiation of the anti-tumor T cell as well as the synergistic anti-tumor effect thereof in a preclinical experiment model.

A method for generating a population of functional regulatory T cells (T_REG-cells), which are a subset of the T cell lineage having the ability to actively suppress immune activation and maintain peripheral immune tolerance, is described. The method comprises the steps of first culturing haemopoietic stem cells (HSC) and/or haemopoietic progenitor cells in the presence of a Notch ligand that supports T cell differentiation, and then isolating T cells having a T_REG-cell surface marker phenotype. A suitable source of HSC is cord blood (CB) and a suitable culture medium is OP9 cells engineered to express the Notch Ligand Delta-Like 1 (DL1) (OP9-DL1 cell line). Examples of T_REG-cell surface marker phenotypes are CD4+CD25+, CD45RO+, CD45RA+, CD127_LOW−, LAG-3 and/or CD39+.

The present invention is to provide an inhibitor that inhibits differentiation of T cells into Th1 cells.

The inhibitor that inhibits differentiation of T cells into Th1 cells contains, as an active ingredient, pitavastatin or a salt thereof.

A method of treating a T-cell mediated disorders in a tissue includes administering to the tissue of the subject a therapeutically effective amount of a complement antagonist that substantially reduces T-cell differentiation or t-cell inflammatory cytokine generation.

The culture method to differentiate embryonic stem cell into T cell comprises: preparing embryo body; transferring the body into differentiated culture medium; digesting the body into single cell by pancreatin; labeling the opposite antibody of T cell special surface cell; detecting T cell quantity with a FCM; and obtaining the need T cell. It also provides the opposite culture medium. This invention overcomes the defect in prior art, induces T lymphocyte from embryonic stem cell directly, and provides a simple and effective external model for research and a safe source for clinical application of T cell.

The invention belongs to the field of biomedicine, and relates to a non-small-cell lung carcinoma molecular marker and applications thereof. According to the present invention, the deep research results show that T cell differentiation protein 2 (MAL2) gene is closely related to the occurrence of non-small-cell lung carcinoma, such that the T cell differentiation protein 2 (MAL2) gene can be usedas the molecular marker for early diagnosis of non-small-cell lung carcinoma; by determining the functions of the key pathogenic gene in non-small-cell lung carcinoma, the molecular target in non-small-cell lung carcinoma can be determined so as to accelerate the progress of the individualized targeted therapy of non-small-cell lung carcinoma; specifically the present invention discloses applications of the MAL2 gene and protein in gene molecular markers for the detection of non-small-cell lung carcinoma, and provides applications of the MAL2 gene and protein in preparation of clinical diagnostic reagents or kits for tumors; and the new gene and the protein highly expressed in non-small-cell lung carcinoma are found so as to provide the new approach for the diagnosis and treatment of tumors.

The present invention relates to new medical use of (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholine-4-yl)methyl-1H-indol-7-yl]amine, and more particularly, to a pharmaceutical composition containing the compound as an active ingredient, which is used for inhibiting an immune response, and/or for inducing differentiation into regulator T cells from undifferentiated T cells and/or promoting proliferation of regulator T cells.

The invention relates to a lymphocyte culture method, and in particular discloses a culturing method of adenovirus gene-modifying tumor specificity cytotoxic T lymphocyte. The method comprises: taking 150-200ml of bleeding of the umbilicus or autologous peripheral blood for single karyocyte separation, separately culturing DC cells by adhering to a wall for 2h, and performing T lymphocyte preculture on the non-adhered cells in an IL-2-contained culture medium; collecting mature DC after the DC cells are mature through induction of iAPA factor adenovirus infection, stimulating the autologous primary T lymphocyte to differentiate into cytotoxic T lymphocyte according to an effect target ratio of DC to T being 1 to 10, and observing and recording multiplication capacity of CTL and detecting the cytotoxicity of the CTL. The limitation of a blood component single sampling machine is solved, collected blood volume is less, burden of a patient is reduced, and iAPA-DC can be observed in vitro to stimulate and differentiate the primary T lymphocyte into tumor specificity cytotoxic T lymphocyte.

Disclosed herein are compositions and methods for enhancing T-cell activity by modulating a miRNA so as to improve T-cell therapies, infectious disease therapies and down-regulate auto-immune responses.

The present invention relates to a composition and a method for inducing CD4⁺ T cells to differentiate into regulatory T cells and proliferate through an induced T cell co-stimulator ligand (ICOSL) or an ICOSL-overexpressing mesenchymal stem cell and for preventing or treating regulatory T cell-mediated diseases. The induced T cell co-stimulator ligand (ICOSL) or ICOSL-overexpressing mesenchymal stem cell according to the present invention effectively suppresses the proliferation of PBMCs, induces the expression of an ICOS in regulatory T cells, thereby inducing the differentiation and proliferation of the regulatory T cells through a PI3K-Akt mechanism, and thus can effectively prevent, treat, or enhance regulatory T cell-mediated diseases.

The invention discloses selenium-doped prussian blue nano-enzyme for regulating intestinal cells to treat colitis, a preparation method and application thereof, wherein a layer of selenium is doped on the surface of hollow mesoporous prussian blue by a hard template method. The selenium-doped prussian blue nano-enzyme disclosed by the invention has a good capability of removing active oxygen and a function of inhibiting intestinal epithelial cell lipid peroxidation and T cell differentiation, and can be used for relieving the occurrence of intestinal inflammatory diseases.

The invention relates to the field of biomedicine, and discloses a biomarker for regulating CD4 + T cells differentiation and proliferation of type 1 diabetes mellitus, which comprises circRNA000324; the invention also discloses an application thereof. According to the invention, a new target is provided for the mechanism research of T1DM autoimmunity, a new evidence is provided for the action mechanism of non-encoding RNA (ncRNA) and related ceRNAs networks in T1DM pathogenesis, and more possibilities are provided for predicting or preventing and treating type 1 diabetes mellitus.